ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

QL1207H

A development code. Also written as “QL1207H injection”.

Its studies are mostly in Macular Degeneration, led by Qilu Pharmaceutical.

Furthest: phase 3, since Mar 18, 20261 company-led study, 1 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical11 open or runningphase 3since Mar 18, 2026Mar 18, 2026Dec 2026phase 3 · NCT07489586

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 18, 2026First study: phase 3 study in Neovascular Age-Related Macular Degeneration (nAMD)First studyNCT07489586 · 356 planned

Ahead

  1. Dec 2026Primary completion: phase 3 study in Neovascular Age-Related Macular Degeneration (nAMD)NCT07489586

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07489586Neovascular Age-Related Macular Degeneration (nAMD)3Not yet recruitingDec 2026356

How it is read

Names in the registry

  • “QL1207H injection”, 1 entry

Codes read as this program: QL1207H.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.